Delivery of RNAi Therapeutics to the Airways—From Bench to Bedside
AbstractRNA interference (RNAi) is a potent and specific post-transcriptional gene silencing process. Since its discovery, tremendous efforts have been made to translate RNAi technology into therapeutic applications for the treatment of different human diseases including respiratory diseases, by manipulating the expression of disease-associated gene(s). Similar to other nucleic acid-based therapeutics, the major hurdle of RNAi therapy is delivery. Pulmonary delivery is a promising approach of delivering RNAi therapeutics directly to the airways for treating local conditions and minimizing systemic side effects. It is a non-invasive route of administration that is generally well accepted by patients. However, pulmonary drug delivery is a challenge as the lungs pose a series of anatomical, physiological and immunological barriers to drug delivery. Understanding these barriers is essential for the development an effective RNA delivery system. In this review, the different barriers to pulmonary drug delivery are introduced. The potential of RNAi molecules as new class of therapeutics, and the latest preclinical and clinical studies of using RNAi therapeutics in different respiratory conditions are discussed in details. We hope this review can provide some useful insights for moving inhaled RNAi therapeutics from bench to bedside. View Full-Text
Share & Cite This Article
Qiu, Y.; Lam, J.K.W.; Leung, S.W.S.; Liang, W. Delivery of RNAi Therapeutics to the Airways—From Bench to Bedside. Molecules 2016, 21, 1249.
Qiu Y, Lam JKW, Leung SWS, Liang W. Delivery of RNAi Therapeutics to the Airways—From Bench to Bedside. Molecules. 2016; 21(9):1249.Chicago/Turabian Style
Qiu, Yingshan; Lam, Jenny K.W.; Leung, Susan W.S.; Liang, Wanling. 2016. "Delivery of RNAi Therapeutics to the Airways—From Bench to Bedside." Molecules 21, no. 9: 1249.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.